Share the post "Gland Pharma announced Financial Results Q1 2024"
Highlights
- The presented financial data is Consolidated to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company experienced a substantial growth of 15.97 % in the past year, decrease in net sales/revenue by -8.83 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 36.98 %. Marginal increase in other income during this quarter, up by 22.02%.
- Profit over the Year and quarter: Challenges in sustaining profitability for Gland Pharma Limited. Profit dropped by -25.94 % Year to Year, Gland Pharma Limited’s profitability dropped by -25.29 % Quarter to Quarter.
- EPS over the Year and quarter: EPS declined by -25.95 % Year to Year. EPS decreased by -25.26 % in previous quarter. Analysis needed for shareholder value.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 1208.693 Cr | Rs. 1537.45 Cr | Rs. 1401.71 Cr | -8.83 % | + 15.97 % |
Expenses | Rs. 914.73 Cr | Rs. 1178.8 Cr | Rs. 1137.31 Cr | -3.52 % | + 24.33 % |
Operating Profit | Rs. 293.96 Cr | Rs. 358.65 Cr | Rs. 264.4 Cr | -26.28 % | -10.06 % |
OPM % | 24.32 % | 23.33 % | 18.86 % | -4.47 % | -5.46 % |
Other Income | Rs. 37.542 Cr | Rs. 42.147 Cr | Rs. 51.426 Cr | + 22.02 % | + 36.98 % |
Interest | Rs. 4.92 Cr | Rs. 9.96 Cr | Rs. 5.62 Cr | -43.57 % | + 14.23 % |
Depreciation | Rs. 65.32 Cr | Rs. 92.61 Cr | Rs. 91.96 Cr | -0.7 % | + 40.78 % |
Profit before tax | Rs. 261.26 Cr | Rs. 298.23 Cr | Rs. 218.25 Cr | -26.82 % | -16.46 % |
Tax % | 25.71 % | 35.48 % | 34.13 % | -1.35 % | + 8.42 % |
Net Profit | Rs. 194.1 Cr | Rs. 192.42 Cr | Rs. 143.76 Cr | -25.29 % | -25.94 % |
EPS in Rs | Rs. 11.78 | Rs. 11.68 | Rs. 8.73 | -25.26 % | -25.89 % |
Today, we’re looking at Gland Pharma Limited’s financial performance for the Q1(Jun 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 15.97 %. However, it did see a marginal slip of -8.83 % from the previous quarter. Expenses decreased slightly by -3.52 % quarter-on-quarter, aligning with the annual rise of 24.33 %. Operating profit, while down -10.06 % compared to last year, faced a quarter-on-quarter dip of -26.28 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -5.46 %, but a shrinkage of -4.47 % sequentially. Other income rose by 22.02 % compared to the last quarter, despite an annual growth of 36.98 %. Interest expenses dropped significantly by -43.57 % from the previous quarter, yet the year-over-year increase remains at a moderate 14.23 %. Depreciation costs fell by -0.7 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 40.78 %. Profit before tax declined annually by -16.46 % but saw a reduction from the preceding quarter by -26.82 %.
Tax expenses as a percentage of profits increased slightly by 8.42 % compared to last year, with a more notable quarter-on-quarter decrease of -1.35 %. Net profit fell by -25.94 % year-on-year but witnessed a -25.29 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -25.89 % but a quarterly fall of -25.26 %. In summary, Gland Pharma Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 1208.693 Cr | Rs. 1537.45 Cr | Rs. 1401.71 Cr | -8.83 % | + 15.97 % |
Expenses | Rs. 914.73 Cr | Rs. 1178.8 Cr | Rs. 1137.31 Cr | -3.52 % | + 24.33 % |
Operating Profit | Rs. 293.96 Cr | Rs. 358.65 Cr | Rs. 264.4 Cr | -26.28 % | -10.06 % |
Net Profit | Rs. 194.1 Cr | Rs. 192.42 Cr | Rs. 143.76 Cr | -25.29 % | -25.94 % |
EPS in Rs | Rs. 11.78 | Rs. 11.68 | Rs. 8.73 | -25.26 % | -25.89 % |
In reviewing Gland Pharma Limited’s 2024(Q1) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 15.97 % year-on-year growth, although there was a slight dip of -8.83 % from the previous quarter. Expenses rose by 24.33 % compared to the previous year, with a decrease of -3.52 % quarter-on-quarter. Operating Profit dropped by -10.06 % annually, and saw a -26.28 % decrease from the last quarter.
Net Profit showed yearly decrease of -25.94 %, and experienced a -25.29 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -25.89 % annually, however dipped by -25.26 % compared to the last quarter. In essence, while Gland Pharma Limited faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.